We are no longer recruiting for the following clinical trials which are active now:

Cassava Sciences PTl-125-06: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76 Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilamin Subjects with Mild to

Moderate Alzheimer’s Disease.

GemVax GV1001-AD-CL2-007: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate AD.

Biogen 221AD305: A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease.

Avanir 17-AVP-786-305: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

Eisai BAN2401-G000-301: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease. Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease.

Biogen 221AD304: Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer’s disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205. 

Eli Lilly I5T-MC-AACI: A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2). Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease.

Otsuka Pharmaceutical Development & Commercialization, Inc. 331-14-213 A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type. Agitation in Alzheimer’s Disease.

Alzheon Apollo E4 ALZ-801-AD301: A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype.

Shanghai Green Valley Pharmaceutical Co. GV971-007: A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer’s Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory). Mild Alzheimer’s Disease to Moderate Alzheimer’s Disease. 

Liva Nova Recover LND 300:  A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects with Treatment-Resistant Depression. Treatment Resistant Depression.

UCB AH0003 – A Patient - and Investigator Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants with Prodromal to Mild Alzheimer’s disease (AD), Followed by an Open Label Extension Period. Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease. 

= Trial is Active No Longer Accepting New Subjects